The Role Of Nanotechnology In Improving Drug Delivery For Lung Cancer

Adel Ahmed Moafa; fathi albadawi Hegaig

المؤلفون

Moafa Adel Ahmed Department of Pharmaceutical Technology faculty of Medical Technology Misurata
fathi albadawi Hegaig Department of Pharmaceutical Technology faculty of Medical Technology Misurata

الكلمات المفتاحية:

Cancer، N.S.C.L.C، S.C.L.C

الملخص

Lung cancer remains one of the deadliest cancers globally, highlighting the urgent need for effective treatment strategies, the aim in this research the potential of nanotechnology in revolutionizing lung cancer treatment, focusing on inhalation chemotherapy and targeted drug delivery systems. The research begins by outlining the characteristics and challenges of lung cancer, emphasizing the importance of early detection and personalized treatment approaches. It then delves into the application of nanotechnology in medicine, specifically highlighting the advantages of nanocarriers for drug delivery, thJanuary and June 2024, The number of male cases was 571, while female cases numbered 515. It is worth noting that there were 95 cases of lung cancer, 80 of which were among males and 15 among females, the most affected age group was those over the age of sixty, Data obtained from the institute indicated that the stage of disease detection for the majority of patients was either unrecorded or possibly unknown. It was also noted that the diagnosis of these cases was not accurate in determining whether the cancer was of the NACLC or SCLC type, The research also explores the development of inhalable formulations for lung cancer treatment, emphasizing the advantages of direct and non-invasive drug delivery to the lungs, leading to improved bioavailability and therapeutic index. The research concludes by highlighting the immense potential of nanotechnology in improving lung cancer treatment outcomes, emphasizing the need for continued research and development of sophisticated nanocarriers capable of effectively targeting and treating lung cancer

السيرة الشخصية للمؤلف

Moafa Adel Ahmed، Department of Pharmaceutical Technology faculty of Medical Technology Misurata

المراجع

- Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):209-249. doi:10.3322/caac21834

- Alamoudi OS. Lung cancer at a University Hospital in Saudi Arabia. Ann Thorac Med. 2010;5(1):30.

- Almoudi OS. Prevalence of respiratory disease in hospitalized patients in Saudi Arabia. Ann Thorac Med. 2006;1(12):76-80.

- Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman M. 2009;101(Suppl 2):S115.

- Lung cancer and smoking. UK. Cancer Stats. Cancer Research UK. 2008.

- Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. 2004;10:179-84.

- Girigoswami, A., & Girigoswami, K. (2023). Potential applications of nanoparticles in improving the outcome of lung cancer treatment. Genes, 14(7), 1370.‏

- Sihoe AD, Yim AP. Lung cancer staging. J Surg Res. 2004;117(1):92-106.

- Liu Y, Cheng W, Xin HY, Liu R, Wang Q, Cai W, Peng X, Yang F, Xin HW. Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy. Nanomedicine. 2023; PMID: 37009262; PMCID: PMC10042676; DOI: 10.1186/s12645-023-00174-x.

- Bahader Y, Jazieh AR. Epidemiology of lung cancer. Annals of Thoracic Medicine. 2008;3(6):65-67.

- Alamoudi OS. Lung cancer at a University Hospital in Saudi Arabia. Annals of Thoracic Medicine. 2010;5(1):30.

- Gupta C, Jaipuria A, Gupta N. Inhalable formulations for treating non-small cell lung cancer (NSCLC): Recent therapies and developments. Pharmaceutics. 2022;15:139.

- Loira-Pastoriza C, Todoroff J, Vanbever R. Delivery strategies for sustained drug release in the lungs. Advanced Drug Delivery Reviews. 2014;75:81-91.

- Lee WH, Loo CY, Traini D, Young PM. Inhalation of nanoparticle-based drugs for lung cancer treatment: Advantages and challenges. Asian Journal of Pharmaceutical Sciences. 2015;10:481-489.

- Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, Bawendi MG, Semmler-Behnke M, Frangioni JV, Tsuda A. Rapid translocation of nanoparticles from the lung airspaces to the body. Nature Biotechnology. 2010;28:1300-1303.

- Rosière R, Amighi K, Wauthoz N. Nanomedicine-Based Inhalation Treatments for Lung Cancer. In: Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer. Kesharwani P (ed). Academic Press. 2019:249-268.

- Sorino C, Negri S, Spanevello A, Visca D, Scichilone N. Inhalation therapy devices for the treatment of obstructive lung diseases: The history of inhalers towards the ideal inhaler. European Journal of Internal Medicine. 2020;75:15-18.

- French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation, and deposition of dry powders for inhalation. Journal of Aerosol Science. 1996;27:769-783.

- Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, Langer R, Edwards DA. Formulation and physical characterization of large porous particles for inhalation. Pharmaceutical Research. 1999;16:1735-1742.

- Kuehl PJ, Grimes MJ, Dubose D, Burke M, Revelli DA, Gigliotti AP, Belinsky SA, Tessema M. Inhalation delivery of topotecan is superior to intravenous exposure for suppressing lung cancer in a preclinical model. Drug Delivery. 2018;25:1127-1136.

- Chraibi S, Rosière R, De Prez E, Gérard P, Antoine MH, Langer I, Nortier J, Remmelink M, Amighi K, Wauthoz N. Preclinical tolerance evaluation of the addition of a cisplatin-based dry powder for inhalation to the conventional carboplatin-paclitaxel doublet for the treatment of non-small cell lung cancer. Biomedicine & Pharmacotherapy. 2021;139:111716.

- Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 2005;23:1147-1157.

- Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: Dawn of a new era? NPJ Precision Oncology. 2023;7:5.

- Shepard KB, Vodak DT, Kuehl PJ, Revelli D, Zhou Y, Pluntze AM, Adam MS, Oddo JC, Switala L, Cape JL, et al. Local treatment of non-small cell lung cancer with a spray-dried bevacizumab formulation. AAPS PharmSciTech. 2021;22:230.

- Maillet A, Congy-Jolivet N, Le Guellec S, Vecellio L, Hamard S, Courty Y, Courtois A, Gauthier F, Diot P, Thibault G, et al. Aerodynamical, immunological, and pharmacological properties of the anticancer antibody cetuximab following nebulization. Pharmaceutical Research. 2008;25:1318-1326.

- Brunaugh AD, Ding L, Wu T, Schneider M, Khalaf R, Smyth HDC. Identification of stability constraints in the particle engineering of an inhaled monoclonal antibody dried powder. Journal of Pharmaceutical Sciences. 2022;111:403-416.

- Cortez-Jugo C, Qi A, Rajapaksa A, Friend JR, Yeo LY. Pulmonary monoclonal antibody delivery via a portable microfluidic nebulization platform. Biomicrofluidics. 2015;9:052603.

- Wang X, Chen H, Zeng X, Guo W, Jin Y, Wang S, Tian R, Han Y, Guo L, Han J, et al. Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system. Acta Pharm Sin B. 2019;9:167-176.

- Ying N, Liu S, Zhang M, Cheng J, Luo L, Jiang J, Shi G, Wu S, Ji J, Su H, et al. Nano delivery system for paclitaxel: Recent advances in cancer theranostics. Colloids and Surfaces B: Biointerfaces. 2023;228:113419.

- Abdel-Rahman M, Stockton D, Rachet B, Hakulinen T, Coleman M. 2009;101(Suppl 2):S115.

- Lung cancer and smoking. UK. Cancer Stats. Cancer Research UK. 2008.

- Al-Ahmadi K, Al-Zahrani A, Al-Ahmadi S. Spatial Accessibility to Cancer Care Facilities in Saudi Arabia.

- Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H. Nanomedicine: challenge and perspectives. Angewandte Chemie International Edition in English. 2009;48:872-897.

- Das SK, Choi S, Yu W, Pradeep T. Nanofluids: Science and Technology. Wiley Interscience, New Jersey. 2007.

- Das T, Bandyopadhyay A, Yeasmin S. Nanoparticles in Lung Cancer Therapy - Recent Trends. 2015. DOI: 10.1007/978-81-322-2175-3.